Edwards Lifesciences Co. (NYSE:EW) VP Sells $327,850.00 in Stock

Edwards Lifesciences Co. (NYSE:EW) VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at $3,077,593.52. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock traded up $0.71 during mid-day trading on Wednesday, reaching $66.52. 3,495,653 shares of the company were exchanged, compared to its average volume of 4,633,185. The company has a fifty day simple moving average of $67.47 and a 200-day simple moving average of $76.51. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The firm has a market cap of $39.23 billion, a PE ratio of 9.56, a PEG ratio of 3.70 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.67. The firm had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The company’s revenue was up 8.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.59 EPS. As a group, equities research analysts expect that Edwards Lifesciences Co. will post 2.57 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

EW has been the subject of a number of recent analyst reports. Evercore ISI reduced their target price on Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating for the company in a report on Tuesday, October 1st. Barclays cut their target price on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research note on Monday, September 9th. Baird R W cut Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 25th. Jefferies Financial Group cut Edwards Lifesciences from a “buy” rating to a “hold” rating and lowered their price target for the company from $85.00 to $70.00 in a report on Wednesday, September 18th. Finally, Wolfe Research upgraded Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a report on Monday, July 29th. Seventeen investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat, Edwards Lifesciences has a consensus rating of “Hold” and an average target price of $75.67.

Hedge Funds Weigh In On Edwards Lifesciences

Several institutional investors have recently bought and sold shares of EW. Park Avenue Securities LLC grew its stake in shares of Edwards Lifesciences by 0.5% in the second quarter. Park Avenue Securities LLC now owns 23,484 shares of the medical research company’s stock worth $2,169,000 after purchasing an additional 108 shares during the last quarter. City State Bank boosted its holdings in Edwards Lifesciences by 16.5% in the 2nd quarter. City State Bank now owns 917 shares of the medical research company’s stock worth $85,000 after buying an additional 130 shares during the period. Stableford Capital II LLC boosted its holdings in Edwards Lifesciences by 2.7% in the 2nd quarter. Stableford Capital II LLC now owns 6,104 shares of the medical research company’s stock worth $533,000 after buying an additional 159 shares during the period. Purus Wealth Management LLC lifted its stake in Edwards Lifesciences by 5.2% in the 2nd quarter. Purus Wealth Management LLC now owns 3,212 shares of the medical research company’s stock worth $297,000 after purchasing an additional 160 shares in the last quarter. Finally, Busey Bank lifted its stake in Edwards Lifesciences by 1.9% in the 2nd quarter. Busey Bank now owns 8,838 shares of the medical research company’s stock worth $816,000 after purchasing an additional 165 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.